The future of ophthalmic topical drug delivery is easy-to-use micro-dosing

EYE-GO is a pre-revenue MedTech company developing a game-changing delivery system for eye care treatment: MistGo

The future of ophthalmic topical drug delivery is easy-to-use micro-dosing

EYE-GO is a pre-revenue MedTech company developing a game-changing delivery system for eye care treatment: MistGo

The future of ophthalmic topical drug delivery is easy-to-use micro-dosing

EYE-GO is a pre-revenue MedTech company developing a game-changing delivery system for eye care treatment: MistGo

It is time to eliminate the flaws with dropper bottle

The way people take eye drops has hardly changed the last century.
Eyedropper bottles are difficult to use and overmedicate the eye simple due to the size of a drop.

See EYE-GO’s one-pagers on micro-dosing and user test in the news section.

 

It is time to eliminate the flaws with dropper bottle

The way people take eye drops has hardly changed the last century.
Eyedropper bottles are difficult to use and overmedicate the eye simple due to the size of a drop.

See EYE-GO’s one-pagers on micro-dosing and user test in the news section.

 

It is time to eliminate the flaws with dropper bottle

The way people take eye drops has hardly changed the last century.
Eyedropper bottles are difficult to use and overmedicate the eye simple due to the size of a drop.

See EYE-GO’s one-pagers on micro-dosing and user test in the news section.

 

MistGo® is a user-friendly,superior alternative to conventional eye drops

EYE-GO has developed a delivery system designed to help patients administer their eye medication in a more precise and friendly way

MistGo® is a user-friendly,superior alternative to conventional eye drops

EYE-GO has developed a delivery system designed to help patients administer their eye medication in a more precise and friendly way

MistGo® is a user-friendly,superior alternative to conventional eye drops

EYE-GO has developed a delivery system designed to help patients administer their eye medication in a more precise and friendly way

Only a fraction of patients achieves the full health outcome of treatment due to imperfections with current eye dop bottles
MistGo® helps patients stay well-medicated

1: Nordstrom et al. Persistence and Adherence With Topical Glaucoma Therapy. Am J. Ophthalmology. 2005 Oct; 140 (4): 598.
2: Stone JL, et al. An Objective Evaluation of Eyedrop Instillation in Patients With Glaucoma. Arch Ophthalmol. 2009;127(6):732–736.

Only a fraction of patients achieves the full health outcome of treatment due to imperfections with current eye dop bottles
MistGo® helps patients stay well-medicated

1: Nordstrom et al. Persistence and Adherence With Topical Glaucoma Therapy. Am J. Ophthalmology. 2005 Oct; 140 (4): 598.
2: Stone JL, et al. An Objective Evaluation of Eyedrop Instillation in Patients With Glaucoma. Arch Ophthalmol. 2009;127(6):732–736.

Only a fraction of patients achieves the full health outcome of treatment due to imperfections with current eye dop bottles
MistGo® helps patients stay well-medicated

1: Nordstrom et al. Persistence and Adherence With Topical Glaucoma Therapy. Am J. Ophthalmology. 2005 Oct; 140 (4): 598.
2: Stone JL, et al. An Objective Evaluation of Eyedrop Instillation in Patients With Glaucoma. Arch Ophthalmol. 2009;127(6):732–736.

Shaping the future of eye-treatment

About MistGo®

 

 

EYE-GO is a Danish pre-revenue MedTech company aiming to improve the quality of life of people dependent on eye medication by offering a highprecision micro-dosing ocular delivery system mitigating the imperfections with current eye drop bottles: MistGo®
EYE-GO has an experienced team, a versatile board of directors comprising, and a supportive circle of owners.

Shaping the future of eye-treatment

About MistGo®

EYE-GO is a Danish pre-revenue MedTech company aiming to improve the quality of life of people dependent on eye medication by offering a highprecision micro-dosing ocular delivery system mitigating the imperfections with current eye drop bottles: MistGo®
EYE-GO has an experienced team, a versatile board of directors comprising, and a supportive circle of owners.

Shaping the future of eye-treatment

About MistGo®

 

EYE-GO is a Danish pre-revenue MedTech company aiming to improve the quality of life of people dependent on eye medication by offering a highprecision micro-dosing ocular delivery system mitigating the imperfections with current eye drop bottles: MistGo®
EYE-GO has an experienced team, a versatile board of directors comprising, and a supportive circle of owners.

MEET EYE-GO’S BOARD OF DIRECTORS

Christian Stig Møller image

Christian Stig Møller

Chairman of the Board

Christian Stig Møller image

Christian Stig Møller

Chairman of the Board

Christian joined EYE-GO as chairman of the board in 2018. He is one of the leading financers in Denmark focused on non-listed investments.At present Christian is partner in Nordic Bloom. For the past 20 years Christian has been CEO in several mid-large size companies in Denmark and abroad including Bank of Copenhagen. Christian also holds the position as Chairman of the Board in several other start-ups and investment funds.

Jacob Dyhr Jensen image

Jacob Dyhr Jensen

Board Member

Jacob Dyhr Jensen image

Jacob Dyhr Jensen

Board Member

Jacob joined EYE-GO as board member in 2023. He has a financial background and currently holds a position as Investment Manager with Maj Invest Equity where he has been employed since 2014. Further, he previously spent time at the life sciences department of the Consulate General of Denmark in New York where he, among other, facilitated contact between American investors and Danish biotech and pharma companies. Jacob brings solid experience when it comes to commercial strategy, financing and M&A.

Ole Feddersen image

Ole Feddersen

Board Member

Ole Feddersen image

Ole Feddersen

Board Member

Ole joined EYE-GO as board member in 2018. He has a solid technical background and important production and supply know-how from many years in key positions within life science and consumer electronics. Currently Ole is the CVP of Device Manufacturing Development at Novo Nordisk. Before he held several senior management positions at Nokia Denmark and latest served as General Manager.

Kim Tosti image

Kim Tosti

Board Member

Kim Tosti image

Kim Tosti

Board Member

Kim joined EYE-GO as board member in 2023. Kim has extensive experience in the pharmaceutical industry as advisor and as former senior executive at Novo Nordisk, specializing in drug and device manufacturing and commercial contracts. Over the years, Kim has actively invested in, studied, and provided support to numerous tech/AI startups. By combining his extensive knowledge in big pharma, start-ups, and AI, Kim has been instrumental in supporting achieving results.

Morten Nielsen image CCO

Morten Nielsen

Board memeber

Morten Nielsen image CCO

Morten Nielsen

Board memeber

Morten joined EYE-GO as board member in 2022. He is a senior executive with strong experience in strategic business transformations and strategy execution. Morten has a background as Partner with PA Consulting Group and has held CEO and other executive positions specializing in Drug Delivery Devices and Connected Health. Morten operates as a MedTech Mentor and holds several board positions.

MEET EYE-GO’S BOARD OF DIRECTORS

Christian Stig Møller image

Christian Stig Møller

Chairman of the Board

Christian Stig Møller image

Christian Stig Møller

Chairman of the Board

Christian joined EYE-GO as chairman of the board in 2018. He is one of the leading financers in Denmark focused on non-listed investments.At present Christian is partner in Nordic Bloom. For the past 20 years Christian has been CEO in several mid-large size companies in Denmark and abroad including Bank of Copenhagen. Christian also holds the position as Chairman of the Board in several other start-ups and investment funds.

Jacob Dyhr Jensen image

Jacob Dyhr Jensen

Board Member

Jacob Dyhr Jensen image

Jacob Dyhr Jensen

Board Member

Jacob joined EYE-GO as board member in 2023. He has a financial background and currently holds a position as Investment Manager with Maj Invest Equity where he has been employed since 2014. Further, he previously spent time at the life sciences department of the Consulate General of Denmark in New York where he, among other, facilitated contact between American investors and Danish biotech and pharma companies. Jacob brings solid experience when it comes to commercial strategy, financing and M&A.

Ole Feddersen image

Ole Feddersen

Board Member

Ole Feddersen image

Ole Feddersen

Board Member

Ole joined EYE-GO as board member in 2018. He has a solid technical background and important production and supply know-how from many years in key positions within life science and consumer electronics. Currently Ole is the CVP of Device Manufacturing Development at Novo Nordisk. Before he held several senior management positions at Nokia Denmark and latest served as General Manager.

Kim Tosti image

Kim Tosti

Board Member

Kim Tosti image

Kim Tosti

Board Member

Kim joined EYE-GO as board member in 2023. Kim has extensive experience in the pharmaceutical industry as advisor and as former senior executive at Novo Nordisk, specializing in drug and device manufacturing and commercial contracts. Over the years, Kim has actively invested in, studied, and provided support to numerous tech/AI startups. By combining his extensive knowledge in big pharma, start-ups, and AI, Kim has been instrumental in supporting achieving results.

Morten Nielsen image CCO

Morten Nielsen

Board memeber

Morten Nielsen image CCO

Morten Nielsen

Board memeber

Morten joined EYE-GO as board member in 2022. He is a senior executive with strong experience in strategic business transformations and strategy execution. Morten has a background as Partner with PA Consulting Group and has held CEO and other executive positions specializing in Drug Delivery Devices and Connected Health. Morten operates as a MedTech Mentor and holds several board positions.

MEET EYE-GO’S BOARD OF DIRECTORS

Christian Stig Møller image

Christian Stig Møller

Chairman of the Board

Christian Stig Møller image

Christian Stig Møller

Chairman of the Board

Christian joined EYE-GO as chairman of the board in 2018. He is one of the leading financers in Denmark focused on non-listed investments.At present Christian is partner in Nordic Bloom. For the past 20 years Christian has been CEO in several mid-large size companies in Denmark and abroad including Bank of Copenhagen. Christian also holds the position as Chairman of the Board in several other start-ups and investment funds.

Jacob Dyhr Jensen image

Jacob Dyhr Jensen

Board Member

Jacob Dyhr Jensen image

Jacob Dyhr Jensen

Board Member

Jacob joined EYE-GO as board member in 2023. He has a financial background and currently holds a position as Investment Manager with Maj Invest Equity where he has been employed since 2014. Further, he previously spent time at the life sciences department of the Consulate General of Denmark in New York where he, among other, facilitated contact between American investors and Danish biotech and pharma companies. Jacob brings solid experience when it comes to commercial strategy, financing and M&A.

Ole Feddersen image

Ole Feddersen

Board Member

Ole Feddersen image

Ole Feddersen

Board Member

Ole joined EYE-GO as board member in 2018. He has a solid technical background and important production and supply know-how from many years in key positions within life science and consumer electronics. Currently Ole is the CVP of Device Manufacturing Development at Novo Nordisk. Before he held several senior management positions at Nokia Denmark and latest served as General Manager.

Kim Tosti image

Kim Tosti

Board Member

Kim Tosti image

Kim Tosti

Board Member

Kim joined EYE-GO as board member in 2023. Kim has extensive experience in the pharmaceutical industry as advisor and as former senior executive at Novo Nordisk, specializing in drug and device manufacturing and commercial contracts. Over the years, Kim has actively invested in, studied, and provided support to numerous tech/AI startups. By combining his extensive knowledge in big pharma, start-ups, and AI, Kim has been instrumental in supporting achieving results.

Morten Nielsen image CCO

Morten Nielsen

Board memeber

Morten Nielsen image CCO

Morten Nielsen

Board memeber

Morten joined EYE-GO as board member in 2022. He is a senior executive with strong experience in strategic business transformations and strategy execution. Morten has a background as Partner with PA Consulting Group and has held CEO and other executive positions specializing in Drug Delivery Devices and Connected Health. Morten operates as a MedTech Mentor and holds several board positions.

MEET EYE-GO’S ADVISORS

Miriam Kolko image

Miriam Kolko

Scientific Advisor

Miriam Kolko image

Miriam Kolko

Scientific Advisor

Professor Miriam Kolko is chief physician and glaucoma
specialist at the Copenhagen University Hospital,
Rigshospitalet and Professor of Translational Eye Research at the Department of Drug Design and Pharmacology at the University of Copenhagen. Miriam is president of the Danish Glaucoma Society, glaucoma chair of EVER, sits in the WGA Associate Advisory Board, and is co-chair for the EGS neuroprotection SIG. Miriam has been scientific advisor for EYE-GO since 2023.

Steffen Heegard

Scientific Advisor

Steffen Heegard

Scientific Advisor

Professor Steffen Heegard is Research Director at
Department of Ophthalmology at the Copenhagen
University Hospital, Rigshospitalet, and professor at
University of Copenhagen. Steffen is president of Danish
ophthalmology society and the European Ocular Oncology Group (OOG) and board member of European Vision and Eye Research. Steffen has been scientific advisor for EYE GO since 2016.

Marie Gunroth Troili image

Marie Gunroth Troili

Commercial Advisor

Marie Gunroth Troili image

Marie Gunroth Troili

Commercial Advisor

Marie is the Former General manager Nordic with
Bausch+Lomb Eye Care. She has a strong background in
sales and marketing with 25 years of experience in the
pharmaceutical and medical device industry. Marie has overseen the strategic direction, operational excellence, financial performance and a diverse portfolio of products and services with B+L. Marie has been commercial advisor for EYE-GO since 2024.

Dave LeCause

Commercial Advisor

Dave LeCause

Commercial Advisor

Dave is the former Vice President with AbbVie – U.S. Eye
Care Sales and Marketing. With over 30 years in Eye
Care, Dave has extensive leadership experience across all areas of commercialization and multiple therapeutic categories, technologies and business models. He has led commercial strategy, launch planning and in-market execution for pre-clinical assets, BD acquired technology and billion-dollar brands. Dave has been commercial advisor for EYE-GO since 2024.

Arnaud Magnier image

Arnaud Magnier

Commercial Advisor

Arnaud Magnier image

Arnaud Magnier

Commercial Advisor

Arnaud is the former General Manager at Abbvie Eye
Care Global Marketing and Commercial Operations.
He has more than 20 years demonstrated success in Commercial Operations in the Healthcare industry managing everything from product launches and portfolio
management, to sales and strategic marketing covering the entre Product Life Cycle span. Arnaud has been commercial advisor for EYE-GO since 2024.

Geert Nygaard image

Geert Nygaard

Commercial Advisor

Geert Nygaard image

Geert Nygaard

Commercial Advisor

Geert is a Senior Executive with a prove track record in
medical diagnositcs. He has international experience from
both large and smnall organizations, a strong commercial
background supported by regulatory and quality
knowledge as well as substantial experience in leading a
publicly listed company and interacting with the financial
community. Geert has been commercial advisor for EYE-GO since 2024.

MEET EYE-GO’S ADVISORS

Miriam Kolko image

Miriam Kolko

Scientific Advisor

Miriam Kolko image

Miriam Kolko

Scientific Advisor

Professor Miriam Kolko is chief physician and glaucoma
specialist at the Copenhagen University Hospital,
Rigshospitalet and Professor of Translational Eye Research at the Department of Drug Design and Pharmacology at the University of Copenhagen. Miriam is president of the Danish Glaucoma Society, glaucoma chair of EVER, sits in the WGA Associate Advisory Board, and is co-chair for the EGS neuroprotection SIG. Miriam has been scientific advisor for EYE-GO since 2023.

Steffen Heegard

Scientific Advisor

Steffen Heegard

Scientific Advisor

Professor Steffen Heegard is Research Director at
Department of Ophthalmology at the Copenhagen
University Hospital, Rigshospitalet, and professor at
University of Copenhagen. Steffen is president of Danish
ophthalmology society and the European Ocular Oncology Group (OOG) and board member of European Vision and Eye Research. Steffen has been scientific advisor for EYE GO since 2016.

Marie Gunroth Troili image

Marie Gunroth Troili

Commercial Advisor

Marie Gunroth Troili image

Marie Gunroth Troili

Commercial Advisor

Marie is the Former General manager Nordic with
Bausch+Lomb Eye Care. She has a strong background in
sales and marketing with 25 years of experience in the
pharmaceutical and medical device industry. Marie has overseen the strategic direction, operational excellence, financial performance and a diverse portfolio of products and services with B+L. Marie has been commercial advisor for EYE-GO since 2024.

Dave LeCause

Commercial Advisor

Dave LeCause

Commercial Advisor

Dave is the former Vice President with AbbVie – U.S. Eye
Care Sales and Marketing. With over 30 years in Eye
Care, Dave has extensive leadership experience across all areas of commercialization and multiple therapeutic categories, technologies and business models. He has led commercial strategy, launch planning and in-market execution for pre-clinical assets, BD acquired technology and billion-dollar brands. Dave has been commercial advisor for EYE-GO since 2024.

Arnaud Magnier image

Arnaud Magnier

Commercial Advisor

Arnaud Magnier image

Arnaud Magnier

Commercial Advisor

Arnaud is the former General Manager at Abbvie Eye
Care Global Marketing and Commercial Operations.
He has more than 20 years demonstrated success in Commercial Operations in the Healthcare industry managing everything from product launches and portfolio
management, to sales and strategic marketing covering the entre Product Life Cycle span. Arnaud has been commercial advisor for EYE-GO since 2024.

Geert Nygaard image

Geert Nygaard

Commercial Advisor

Geert Nygaard image

Geert Nygaard

Commercial Advisor

Geert is a Senior Executive with a prove track record in
medical diagnositcs. He has international experience from
both large and smnall organizations, a strong commercial
background supported by regulatory and quality
knowledge as well as substantial experience in leading a
publicly listed company and interacting with the financial
community. Geert has been commercial advisor for EYE-GO since 2024.

MEET EYE-GO’S ADVISORS

Miriam Kolko image

Miriam Kolko

Scientific Advisor

Miriam Kolko image

Miriam Kolko

Scientific Advisor

Professor Miriam Kolko is chief physician and glaucoma
specialist at the Copenhagen University Hospital,
Rigshospitalet and Professor of Translational Eye Research at the Department of Drug Design and Pharmacology at the University of Copenhagen. Miriam is president of the Danish Glaucoma Society, glaucoma chair of EVER, sits in the WGA Associate Advisory Board, and is co-chair for the EGS neuroprotection SIG. Miriam has been scientific advisor for EYE-GO since 2023.

Steffen Heegard

Scientific Advisor

Steffen Heegard

Scientific Advisor

Professor Steffen Heegard is Research Director at
Department of Ophthalmology at the Copenhagen
University Hospital, Rigshospitalet, and professor at
University of Copenhagen. Steffen is president of Danish
ophthalmology society and the European Ocular Oncology Group (OOG) and board member of European Vision and Eye Research. Steffen has been scientific advisor for EYE GO since 2016.

Marie Gunroth Troili image

Marie Gunroth Troili

Commercial Advisor

Marie Gunroth Troili image

Marie Gunroth Troili

Commercial Advisor

Marie is the Former General manager Nordic with
Bausch+Lomb Eye Care. She has a strong background in
sales and marketing with 25 years of experience in the
pharmaceutical and medical device industry. Marie has overseen the strategic direction, operational excellence, financial performance and a diverse portfolio of products and services with B+L. Marie has been commercial advisor for EYE-GO since 2024.

Dave LeCause

Commercial Advisor

Dave LeCause

Commercial Advisor

Dave is the former Vice President with AbbVie – U.S. Eye
Care Sales and Marketing. With over 30 years in Eye
Care, Dave has extensive leadership experience across all areas of commercialization and multiple therapeutic categories, technologies and business models. He has led commercial strategy, launch planning and in-market execution for pre-clinical assets, BD acquired technology and billion-dollar brands. Dave has been commercial advisor for EYE-GO since 2024.

Arnaud Magnier image

Arnaud Magnier

Commercial Advisor

Arnaud Magnier image

Arnaud Magnier

Commercial Advisor

Arnaud is the former General Manager at Abbvie Eye
Care Global Marketing and Commercial Operations.
He has more than 20 years demonstrated success in Commercial Operations in the Healthcare industry managing everything from product launches and portfolio
management, to sales and strategic marketing covering the entre Product Life Cycle span. Arnaud has been commercial advisor for EYE-GO since 2024.

Geert Nygaard image

Geert Nygaard

Commercial Advisor

Geert Nygaard image

Geert Nygaard

Commercial Advisor

Geert is a Senior Executive with a prove track record in
medical diagnositcs. He has international experience from
both large and smnall organizations, a strong commercial
background supported by regulatory and quality
knowledge as well as substantial experience in leading a
publicly listed company and interacting with the financial
community. Geert has been commercial advisor for EYE-GO since 2024.

MistGo® – the future of eye-treatmentsasasa

MistGo® – the future of eye-treatmentsasasa

MistGo® – the future of eye-treatmentsasasa

MistGo® is a user-friendly, superior alternative to conventional eye drops

  • I Drops

    I Drops

    Mist Go

    Mist Go

  • Micro dosing ability & precision

    Low

    High

    Optimal dose. Precise instillation. Every time.

  • Ease of use and comfort for patient

    Low

    High

    Easy and comfortable to use for all patients

  • Risk of cross contamination

    High

    Low

    Avoids cross contamination or trauma in the eye

  • Preservative free drug compatibility

    Low

    High

    Compatible with preservative free substances

MistGo® is a user-friendly, superior alternative to conventional eye drops

  • I Drops

    I Drops

    Mist Go

    Mist Go

  • Micro dosing ability & precision

    Low

    High

    Optimal dose. Precise instillation. Every time.

  • Ease of use and comfort for patient

    Low

    High

    Easy and comfortable to use for all patients

  • Risk of cross contamination

    High

    Low

    Avoids cross contamination or trauma in the eye

  • Preservative free drug compatibility

    Low

    High

    Compatible with preservative free substances

MistGo® is a user-friendly, superior alternative to conventional eye drops

  • I Drops

    I Drops

    Mist Go

    Mist Go

  • Micro dosing ability & precision

    Low

    High

    Optimal dose. Precise instillation. Every time.

  • Ease of use and comfort for patient

    Low

    High

    Easy and comfortable to use for all patients

  • Risk of cross contamination

    High

    Low

    Avoids cross contamination or trauma in the eye

  • Preservative free drug compatibility

    Low

    High

    Compatible with preservative free substances

Poor installation techniques jeopardizes compliance to treatment

Of the routes to administer drugs to the eye, the topical route is the most used. Unfortunately, the design of the eye drop bottle leads many patients to administer their medication incorrectly.

Studies prove that among glaucoma patients, the proportion of patients using improper technique ranges from 34% to 92%. 7-44% miss the eye completely and 18-80% contaminate the tip of the bottle by contacting the eye or surrounding tissue.

 

 

Poor installation techniques jeopardizes compliance to treatment

Of the routes to administer drugs to the eye, the topical route is the most used. Unfortunately, the design of the eye drop bottle leads many patients to administer their medication incorrectly.

Studies prove that among glaucoma patients, the proportion of patients using improper technique ranges from 34% to 92%. 7-44% miss the eye completely and 18-80% contaminate the tip of the bottle by contacting the eye or surrounding tissue.

 

 

Poor installation techniques jeopardizes compliance to treatment

Of the routes to administer drugs to the eye, the topical route is the most used. Unfortunately, the design of the eye drop bottle leads many patients to administer their medication incorrectly.

Studies prove that among glaucoma patients, the proportion of patients using improper technique ranges from 34% to 92%. 7-44% miss the eye completely and 18-80% contaminate the tip of the bottle by contacting the eye or surrounding tissue.

 

 

Studies show that micro-dosing is as safe and efficacious as normal eye-drops

Medicating with an eye dropper result in a drop containing 30-50 μl which greatly exceeds the physiologic 6-8 μL ocular tear film capacity.

A part of the delivered solution is washed out of the eye, but up to 80% of the dose enters the systemic circulation via transport into surface blood vessels or passage through the nasal lacrimal duct and into the digestive system, leading to an increased risk of systemic adverse events.

Any excess solution remaining in the eye can lead to local adverse events, incl. hypersensitivity reactions to the drug or excipients.

From a biopharmaceutical and economic point of view, the ideal would be to instill smaller volumes of eye medication as they can achieve a maximal tear film concentration with far less systemic absorption.

Studies show that micro-dosing is as safe and efficacious as normal eye-drops

Medicating with an eye dropper result in a drop containing 30-50 μl which greatly exceeds the physiologic 6-8 μL ocular tear film capacity.

A part of the delivered solution is washed out of the eye, but up to 80% of the dose enters the systemic circulation via transport into surface blood vessels or passage through the nasal lacrimal duct and into the digestive system, leading to an increased risk of systemic adverse events.

Any excess solution remaining in the eye can lead to local adverse events, incl. hypersensitivity reactions to the drug or excipients.

From a biopharmaceutical and economic point of view, the ideal would be to instill smaller volumes of eye medication as they can achieve a maximal tear film concentration with far less systemic absorption.

Studies show that micro-dosing is as safe and efficacious as normal eye-drops

Medicating with an eye dropper result in a drop containing 30-50 μl which greatly exceeds the physiologic 6-8 μL ocular tear film capacity.

A part of the delivered solution is washed out of the eye, but up to 80% of the dose enters the systemic circulation via transport into surface blood vessels or passage through the nasal lacrimal duct and into the digestive system, leading to an increased risk of systemic adverse events.

Any excess solution remaining in the eye can lead to local adverse events, incl. hypersensitivity reactions to the drug or excipients.

From a biopharmaceutical and economic point of view, the ideal would be to instill smaller volumes of eye medication as they can achieve a maximal tear film concentration with far less systemic absorption.

MistGo® is designed to micro-dose

MistGo® contains a high-precision micropump, consistently metering a dose of 6 μL, dispensing no excess liquid to irritate the skin, enter systemic circulation or risk adverse events.

The internal geometry of the nozzle is designed to vaporise the drug into a fine mist with a broad impact pattern, coating the entire cornea for optimal absorption (~10-12 mm diameter).

MistGo® is designed to micro-dose

MistGo® contains a high-precision micropump, consistently metering a dose of 6 μL, dispensing no excess liquid to irritate the skin, enter systemic circulation or risk adverse events.

The internal geometry of the nozzle is designed to vaporise the drug into a fine mist with a broad impact pattern, coating the entire cornea for optimal absorption (~10-12 mm diameter).

MistGo® is designed to micro-dose

MistGo® contains a high-precision micropump, consistently metering a dose of 6 μL, dispensing no excess liquid to irritate the skin, enter systemic circulation or risk adverse events.

The internal geometry of the nozzle is designed to vaporise the drug into a fine mist with a broad impact pattern, coating the entire cornea for optimal absorption (~10-12 mm diameter).

Preservative-free eye medication requires sterility in delivery system

Eye drops delivered in a multidose container must maintain sterility of the contents throughout the use period, as microbial keratitis is a
risk for users of topical ophthalmic solutions upon accidental contamination of the product.

Antimicrobial activity is often achieved through the addition of
preservatives – the most frequently used benzalkonium chloride (BAK) – which due to toxicity have deleterious effects on the ocular surface.

Removal of the preservative eliminates preservative-induced complications.

A preservative free eye medication must be dispensed in a delivery system designed to keep the liquid formulation sterile
throughout the treatment period.

Preservative-free eye medication requires sterility in delivery system

Eye drops delivered in a multidose container must maintain sterility of the contents throughout the use period, as microbial keratitis is a
risk for users of topical ophthalmic solutions upon accidental contamination of the product.

Antimicrobial activity is often achieved through the addition of
preservatives – the most frequently used benzalkonium chloride (BAK) – which due to toxicity have deleterious effects on the ocular surface.

Removal of the preservative eliminates preservative-induced complications.

A preservative free eye medication must be dispensed in a delivery system designed to keep the liquid formulation sterile
throughout the treatment period.

Preservative-free eye medication requires sterility in delivery system

Eye drops delivered in a multidose container must maintain sterility of the contents throughout the use period, as microbial keratitis is a
risk for users of topical ophthalmic solutions upon accidental contamination of the product.

Antimicrobial activity is often achieved through the addition of
preservatives – the most frequently used benzalkonium chloride (BAK) – which due to toxicity have deleterious effects on the ocular surface.

Removal of the preservative eliminates preservative-induced complications.

A preservative free eye medication must be dispensed in a delivery system designed to keep the liquid formulation sterile
throughout the treatment period.

MistGo® – can be used for medication both with and without preservatives

MistGo® is airtight and designed to maintain sterility in the following way:

  • Integrates a collapsible multilayer cartridge obviating air ventilation.
    No backflow of (contaminated) air requiring filtering.
  • The liquid is sealed off from the environment using nonpermeable
    materials. Several barriers are established to separate the liquid
    from the environment.
  • The system enables pressurized air to both create the mist and
    completely clean the outlet nozzle chamber after dispensing. The
    liquid column is broken, and no liquid is left for later microbiocidal
    contamination.
  • An eye interface protects the nozzle from contamination caused by
    user contact, and a lid helps protect the dosing chamber during
    storage between use.

MistGo® – can be used for medication both with and without preservatives

MistGo® is airtight and designed to maintain sterility in the following way:

  • Integrates a collapsible multilayer cartridge obviating air ventilation.
    No backflow of (contaminated) air requiring filtering.
  • The liquid is sealed off from the environment using nonpermeable
    materials. Several barriers are established to separate the liquid
    from the environment.
  • The system enables pressurized air to both create the mist and
    completely clean the outlet nozzle chamber after dispensing. The
    liquid column is broken, and no liquid is left for later microbiocidal
    contamination.
  • An eye interface protects the nozzle from contamination caused by
    user contact, and a lid helps protect the dosing chamber during
    storage between use.

MistGo® – can be used for medication both with and without preservatives

MistGo® is airtight and designed to maintain sterility in the following way:

  • Integrates a collapsible multilayer cartridge obviating air ventilation.
    No backflow of (contaminated) air requiring filtering.
  • The liquid is sealed off from the environment using nonpermeable
    materials. Several barriers are established to separate the liquid
    from the environment.
  • The system enables pressurized air to both create the mist and
    completely clean the outlet nozzle chamber after dispensing. The
    liquid column is broken, and no liquid is left for later microbiocidal
    contamination.
  • An eye interface protects the nozzle from contamination caused by
    user contact, and a lid helps protect the dosing chamber during
    storage between use.

MistGo® has a large performance window and is customizable to many drugs – including the sticky ones

Parameters in MistGo® can be customized to suit the needs of individual drugs including those with high viscosity enabling the delivery system to perform optimally for liquids for a variety of both RX (prescription) and OTC (over the counter) medicines

  • Micro-dosing: a high-precision pump consistently meters a dose of 6 μL, dispensing no excess liquid to irritate the skin or enter systemic circulation.
  • Delivery time: the dose is fully delivered before the eye can blink
  • Gentle: the internal geometry of the nozzle is optimized to vaporize the liquid into a fine mist of micro droplets, which feels comfortable and soothing in the eye compared to a single dense drop
  • Precision: the entire mist is delivered precisely within the target area: the cornea (11mm diameter when the eye is fully open)

MistGo® has a large performance window and is customizable to many drugs – including the sticky ones

Parameters in MistGo® can be customized to suit the needs of individual drugs including those with high viscosity enabling the delivery system to perform optimally for liquids for a variety of both RX (prescription) and OTC (over the counter) medicines

  • Micro-dosing: a high-precision pump consistently meters a dose of 6 μL, dispensing no excess liquid to irritate the skin or enter systemic circulation.
  • Delivery time: the dose is fully delivered before the eye can blink
  • Gentle: the internal geometry of the nozzle is optimized to vaporize the liquid into a fine mist of micro droplets, which feels comfortable and soothing in the eye compared to a single dense drop
  • Precision: the entire mist is delivered precisely within the target area: the cornea (11mm diameter when the eye is fully open)

MistGo® has a large performance window and is customizable to many drugs – including the sticky ones

Parameters in MistGo® can be customized to suit the needs of individual drugs including those with high viscosity enabling the delivery system to perform optimally for liquids for a variety of both RX (prescription) and OTC (over the counter) medicines

  • Micro-dosing: a high-precision pump consistently meters a dose of 6 μL, dispensing no excess liquid to irritate the skin or enter systemic circulation.
  • Delivery time: the dose is fully delivered before the eye can blink
  • Gentle: the internal geometry of the nozzle is optimized to vaporize the liquid into a fine mist of micro droplets, which feels comfortable and soothing in the eye compared to a single dense drop
  • Precision: the entire mist is delivered precisely within the target area: the cornea (11mm diameter when the eye is fully open)

Let’s improve your Patient Pharma company value proposition and increase patients’ quality of life

Contact EYE-GO
Patient
  • Reduced dosing uncertainty
  • Reduced systemic exposure
  • Reduced side effects
  • Reduced stigmatization
  • Better usability & convenience
  • Precise drug administration
  • Better disease management
  • Higher patient quality of life
  • sasas
  • asas
  • asas
Pharma Company
  • Better value selling
  • More patient-centric
  • More versatile user/use profile
  • Reduced stigmatization
  • Higher clinical outcome
  • Higher brand loyalty
  • Extended product life cycle
  • Realize full business potential

Let’s improve your Patient Pharma company value proposition and increase patients’ quality of life

Contact EYE-GO
Patient
  • Reduced dosing uncertainty
  • Reduced systemic exposure
  • Reduced side effects
  • Reduced stigmatization
  • Better usability & convenience
  • Precise drug administration
  • Better disease management
  • Higher patient quality of life
  • sasas
  • asas
  • asas
Pharma Company
  • Better value selling
  • More patient-centric
  • More versatile user/use profile
  • Reduced stigmatization
  • Higher clinical outcome
  • Higher brand loyalty
  • Extended product life cycle
  • Realize full business potential

Let’s improve your Patient Pharma company value proposition and increase patients’ quality of life

Contact EYE-GO
Patient
  • Reduced dosing uncertainty
  • Reduced systemic exposure
  • Reduced side effects
  • Reduced stigmatization
  • Better usability & convenience
  • Precise drug administration
  • Better disease management
  • Higher patient quality of life
  • sasas
  • asas
  • asas
Pharma Company
  • Better value selling
  • More patient-centric
  • More versatile user/use profile
  • Reduced stigmatization
  • Higher clinical outcome
  • Higher brand loyalty
  • Extended product life cycle
  • Realize full business potential

Get in touch with us

Contact us today to learn more about how MistGo® can help your
ophthalmic therapeutic treatment perform to its best.

INFO@EYE-GO.COM

This field is for validation purposes and should be left unchanged.

Get in touch with us

Contact us today to learn more about how MistGo® can help your
ophthalmic therapeutic treatment perform to its best.

INFO@EYE-GO.COM

This field is for validation purposes and should be left unchanged.

Get in touch with us

Contact us today to learn more about how MistGo® can help your
ophthalmic therapeutic treatment perform to its best.

INFO@EYE-GO.COM

This field is for validation purposes and should be left unchanged.